Company intelligence / Profile preview

G1 Therapeutics, Inc.

Research Triangle Park, North Carolina, United Statesg1therapeutics.com ↗

Ownership: Public · GTHX
Development stage: Commercial

Overview

G1 Therapeutics has a commercial product COSELA (trilaciclib), which is FDA-approved for use in extensive-stage small cell lung cancer. The company has multiple ongoing Phase 2 and Phase 3 clinical trials evaluating trilaciclib in various cancer indications including colorectal, breast, lung, and bladder cancers. Initial results from the pivotal Phase 3 PRESERVE 1 trial in colorectal cancer were expected in February 2023. The company is exploring trilaciclib's potential synergistic effects with chemotherapy, antibody drug conjugates (ADCs), and checkpoint inhibitors.

Therapeutic areas: Oncology
Modalities: Small moleculesCDK4/6 inhibitorsSelective estrogen receptor degraders (SERD)
Industry: Biotech

Drug pipeline

4 assets

trilaciclib

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

Genentech (Roche Group)AstraZenecaGeneCentric Therapeutics

Financials

Market cap: $377.7M
Total revenue: $16.5M
Enterprise value: $364.9M

Beyond the preview

Go deeper on G1 Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G1 Therapeutics, Inc..

Explore the full profile